Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 23, 2009

Alethia Obtains $2.2M Financing to Advance Preclinical mAbs

  • Alethia Biotherapeutics received a $2.2 million investment. The financing was led by GO Capital Fund and BDC Venture Capital. Epicentre Technologies and Alethia founders, Yves Cornellier and Mario Filion, also participated.

    “These funds represent the first step toward the closing of a presently evolving Series A round that will help bring our lead therapeutics into the clinic,” remarks Cornellier, president and CEO. Alethia's mAb programs are focused in three indications.

    The company's most advanced mAb targets a secreted factor called clusterin, which plays a role in tumor progression and invasion. AB-0447 is being developed against an antigen that reportedly is over-expressed in more than 90% of ovarian tumors.

    The firm’s severe bone loss program targets AB-0440, a cell surface protein that is stimulated during early osteoclast differentiation. Lead candidates in this program are currently under evaluation for animal studies.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »